Skip Navigation
Menu
Editorials |16 April 2019

A Guide to a Guidance Statement on Screening Guidelines

Joann G. Elmore, MD, MPH; Christoph I. Lee, MD, MS

Article, Author, and Disclosure Information
Author, Article, and Disclosure Information
This article was published at Annals.org on 9 April 2019.
  • David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California (J.G.E.)
    University of Washington School of Medicine, Seattle, Washington (C.I.L.)

    Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M19-0726.

    Corresponding Author: Joann G. Elmore, MD, MPH, Department of Medicine, David Geffen School of Medicine at UCLA, 1100 Glendon Avenue, Suite 900, Los Angeles, CA 90024; e-mail, JElmore@mednet.ucla.edu.

    Current Author Addresses: Dr. Elmore: Department of Medicine, David Geffen School of Medicine at UCLA, 1100 Glendon Avenue, Suite 900, Los Angeles, CA 90024.

    Dr. Lee: University of Washington School of Medicine, 1144 Eastlake Avenue East, LG-200, Seattle, WA 98109.

×
FULL TEXT
In this issue, the American College of Physicians (ACP) Clinical Guidelines Committee presents its assessment of the quality and content of 7 English-language guidelines for breast cancer screening (1). The results of the assessment are 4 guidance statements that provide clarity and simplicity amidst the chaos of diverging guidelines. ACP guidance statements represent convergence across differing recommendations while highlighting important points for physicians to consider in shared decision-making conversations with their patients about routine breast cancer screening.
Variability in the interpretation of medical data has long been studied (2) and is a known phenomenon in breast cancer screening, both in radiologists' subjective interpretation of mammograms (3) and in objective interpretation of data from randomized clinical trials. Indeed, there is also marked variability in the makeup of screening guideline bodies, and research has shown conflict-of-interest issues related to authors' clinical specialties in earlier mammography guidelines (4). Of note, even among the members of the ACP Clinical Guidelines Committee, assessment and quality ratings varied considerably. These ACP guidance statements were developed after review of guidelines familiar to most screening stakeholders, including guidance from the U.S. Preventive Services Task Force, American Cancer Society, American College of Radiology, American College of Obstetricians and Gynecologists, Canadian Task Force on Preventive Health Care, National Comprehensive Cancer Network, and the World Health Organization.
The Committee ultimately agreed on 4 general guidance statements: First, in average-risk women aged 40 to 49 years, clinicians should discuss whether to screen for breast...
FULL TEXT
PDF
Not Available
Citations
Citation

Elmore JG, Lee CI. A Guide to a Guidance Statement on Screening Guidelines. Ann Intern Med. [Epub ahead of print 9 April 2019]170:573–574. doi: 10.7326/M19-0726

Download citation file:

© 2019

×
Permissions

Published: Ann Intern Med. 2019;170(8):573-574.

DOI: 10.7326/M19-0726

Published at www.annals.org on 9 April 2019

©
2019 American College of Physicians
0 Citations

Related Articles
Methods for Development of the European Commission Initiative on Breast Cancer Guidelines: Recommendations in the Era of Guideline Transparency
Annals of Internal Medicine; 171 (4): 273-280
Models in the Development of Clinical Practice Guidelines
Annals of Internal Medicine; 161 (11): 812-818
Beyond “Heal Thyself”: Physicians as Patients—An Uneasy Role
Annals of Internal Medicine; 170 (12): 893-894
Contemporary Implications of U.S. Preventive Services Task Force and Risk-Based Guidelines for Lung Cancer Screening Eligibility in the United States
Annals of Internal Medicine; ():
View MoreView Less

Journal Club
ACC/AHA guidelines determining statin eligibility better predicted CVD than ATP-III guidelines
Annals of Internal Medicine; 163 (10): JC11
Review: In women ≥ 40 years of age at average risk, breast cancer screening causes some harms
Annals of Internal Medicine; 164 (8): JC39
Annual mammography screening did not reduce long-term breast cancer mortality in women 40 to 59 years of age
Annals of Internal Medicine; 160 (10): JC7
4% lidocaine gel applied to the breasts before screening mammography reduced discomfort
Annals of Internal Medicine; 149 (10): JC5-9
View MoreView Less

Related Point of Care
Breast Cancer Screening and Prevention
Annals of Internal Medicine; 164 (11): ITC81-ITC96
Breast Cancer Screening and Prevention
Annals of Internal Medicine; 152 (7): ITC4-1
View MoreView Less

Related Topics
Breast Cancer
Cancer Screening/Prevention
Hematology/Oncology
Prevention/Screening

Breast Cancer, Cancer Screening/Prevention, Hematology/Oncology, Prevention/Screening.

CONTINUE WITH LIMITED ACCESS
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
acp link acp
silverchair link silverchair

Copyright © 2019 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy. | Accept
×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×